BRM is a successful biopharmaceutical company formed in 1996 by Dennis Guberski and Dr. Arthur Like of the University of Massachusetts Medical School (UMass). Over the course of 20 years the founders developed proprietary diabetes research models under the sponsorship of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK). BRM licensed this intellectual property portfolio from UMass in 1998 and since that time has used these proprietary tools to become one of the leading sources of customized preclinical contract research specializing in type 1 and type 2 diabetes.
BRM has developed proprietary rat strains which are translatable models for the characterization of type 1 and type 2 diabetes as well as immune-related diseases. Its technical competencies include design and conducting studies in autoimmunity (type 1 diabetes, lupus, Rheumatoid Arthritis and Multiple Sclerosis), metabolic disease (type 2 diabetes, metabolic syndrome, obesity, dyslipidemia, liver and kidney function), virology, neurodegenerative diseases, diabetic complications (retinopathy, neuropathy, nephropathy, and encephalopathy including Alzheimer’s disease) specialized animal model development and the production and care of multiple species.
BRM's Capabilities in Virology, Viral Immunology and Pathology: HSV-1, HSV-2, Influenza, RSV, LCMV, and CMV. For more information, please visit our website at www.BRMCRO.com.
BRM is a successful biopharmaceutical company formed in 1996 by Dennis Guberski and Dr. Arthur Like of the University of Massachusetts Medical School (UMass). Over the course of 20 years the founders developed proprietary diabetes research models under the sponsorship of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK). BRM licensed this intellectual property portfolio from UMass in 1998 and since that time has used these proprietary tools to become one of the leading sources of customized preclinical contract research specializing in type 1 and type 2 diabetes.
BRM has developed proprietary rat strains which are translatable models for the characterization of type 1 and type 2 diabetes as well as immune-related diseases. Its technical competencies include design and conducting studies in autoimmunity (type 1 diabetes, lupus, Rheumatoid Arthritis and Multiple Sclerosis), metabolic disease (type 2 diabetes, metabolic syndrome, obesity, dyslipidemia, liver and kidney function), virology, neurodegenerative diseases, diabetic complications (retinopathy, neuropathy, nephropathy, and encephalopathy including Alzheimer’s disease) specialized animal model development and the production and care of multiple species.
BRM's Capabilities in Virology, Viral Immunology and Pathology: HSV-1, HSV-2, Influenza, RSV, LCMV, and CMV. For more information, please visit our website at www.BRMCRO.com.